Since the first generation of rapamycin analogs and mTOR inhibitors, both selective and multi-target PI3K/Akt inhibitors have been developed and may have a crucial role in advanced BC treatment in the forthcoming years. The gene discussed is AKT1; the disease is breast cancer.